You are here: Home » Current Affairs » Coronavirus » News
Business Standard

Supply order for Covishield was placed after drug regulator's nod: Govt

The Rajya Sabha was informed about this on Tuesday

Coronavirus Vaccine | Bharat Biotech | Rajya Sabha

Press Trust of India  |  New Delhi 

Representational image of Covishield

For the procurement of COVID-19 vaccines, a supply order dated January 11 was placed with the Serum Institute of India after Covishield was approved for restricted use in emergency situation by India's drug regulator, the was informed on Tuesday.

Union Minister of State for Health Ashwini Choubey was responding to a question on whether the government has finalised a pricing and supply agreement with the Serum Institute of India Limited for COVID-19 vaccines.

Covishield is being manufactured by the Pune-based firm with technology transfer from AstraZeneca/Oxford University.

On whether it is a fact that multiple doses of the vaccine produced for India could not be rolled out despite approval due to the lack of a formal agreement for supply, Choubey, in a written reply, said, " No. As per protocol, the supply order for COVID-19 vaccines, specifying the number of vaccine doses, was placed with the manufacturer and vaccines were delivered within 3 days to the states and UTs and other consignee points.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Tue, February 02 2021. 14:30 IST